Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986178 Alone or with Nivolumab/Ipilimumab in Advanced Solid Tumors
NCT02737475Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2016
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of BMS-986178 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), sponsored by Bristol Myers Squibb. Started Jun 2016; status: completed.
02
Drugs
BMS-986178
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02737475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737475.